ASIT biotech is restructuring after the failure of its lead product.
More ASIT biotech content >Investment summary
Edison Investment Research is terminating coverage on Abacus Health Products (ABCS), ADL Bionatur (BNT), ASIT Biotech (ASIT), GAME Digital (GMD), International Stem Cell Corporation (ISCO), Powerhouse Energy Group (PHE), Windar Photonics (WPHO). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
---|---|---|---|---|---|---|
2017A | 0.0 | (12.0) | (12.0) | (93.6) | N/A | N/A |
2018A | 0.0 | (12.8) | (14.3) | (85.7) | N/A | N/A |
2019E | N/A | N/A | N/A | N/A | N/A | N/A |
2020E | N/A | N/A | N/A | N/A | N/A | N/A |
Industry outlook
Reported gp-ASIT+ Phase III allergy data showed a statistically proven but inadequate clinical response.
Last updated on 04/09/2020Content on ASIT biotech
ASIT biotech – Statistically significant clinical insignificance
Healthcare
|
research Update
|
26 November 2019




ASIT biotech – Building to a crescendo
Healthcare
|
research Update
|
19 September 2019




Executive interview – ASIT Biotech
Healthcare
|
Edison TV
|
23 July 2019
Sector |
---|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
---|---|
Forecast net debt (€m) | N/A |
Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
Key management |
|
---|---|
Michel Baijot | CEO |
Frank Hazevoets | CFO |
Yves Desiront | CFO |
You may also be interested in…
- Abliva
- AlzeCure Pharma
- Basilea Pharmaceutica
- BerGenBio
- Cantargia
- Carmat
- Deinove
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- IRLAB Therapeutics
- Kiadis Pharma
- MagForce
- Medigene
- MOLOGEN
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- RhoVac
- Ryvu Therapeutics
- Scandion Oncology
- Sequana Medical
- Targovax
- Transgene
- TxCell
- Ultimovacs
- Vivesto
- Xbrane Biopharma